Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 20/20 | 0.51 |
| ▸ | MMP13 | P45452 | 19/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754086 | 0.81 | MMP1 (0.58) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL7440416 | 0.80 | MMP1 (0.59) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL5814098 | 0.80 | MMP1 (0.56) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6756489 | 0.77 | CA12 (0.48) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6501396 | 0.76 | MMP1 (0.67) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL7079076 | 0.76 | MMP1 (0.45) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6501047 | 0.76 | MMP1 (0.67) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6500973 | 0.75 | MMP1 (0.74) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6756495 | 0.74 | MMP1 (0.68) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6757484 | 0.73 | MMP1 (0.57) | MMP1ADAM17MMP13MMP9ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | MMP1 203/4885ADAM17 30/4885MMP13 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.